Undisclosed Antibody Pipeline

About Kekkan Biologics

Kekkan Biologics is a Paris-based, preclinical-stage biotech leveraging over 20 years of foundational research in tumor angiogenesis and lymphangiogenesis to build a pipeline of novel biologics. The company focuses on severe neovascular and fibrotic disorders, including metastatic cancers, by targeting key pathways in blood and lymphatic vessel formation. Founded by a complementary team of scientists and business professionals, it is incubated at SEMIA in Strasbourg and guided by a strong Translational Advisory Board of oncology experts. Kekkan operates as a platform company, aiming to generate multiple antibody candidates from its core research.

Therapeutic Areas